Status:
RECRUITING
Plasma Pharmacological Monitoring of M Penicillins in Methicillin-sensitive Staphylococcus Aureus Bacteremia
Lead Sponsor:
University Hospital, Strasbourg, France
Conditions:
Staphylococcus Aureus Infection
Eligibility:
All Genders
18+ years
Brief Summary
The treatment of Methicillin-sensitive Staphylococcus aureus bacteremia is based on the first-line use of cefazolin or M penicillins (oxacillin and cloxacillin). The use of the latter is recommended a...
Eligibility Criteria
Inclusion
- Adult patient (≥18 years old)
- Having presented an infection with Staphylococcus aureus and treated at the University Hospitals of Strasbourg between January 1, 2019 and December 31, 2022.
Exclusion
- \- Patient having expressed his opposition to the reuse of his data for scientific research purposes.
Key Trial Info
Start Date :
July 19 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 19 2024
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06495697
Start Date
July 19 2023
End Date
July 19 2024
Last Update
July 11 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Service des Maladies Infectieuses et Tropicales - CHU de Strasbourg - France
Strasbourg, France, 67091